



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 52812

**Title:** Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: result from a retrospective study on 38 Chinese patients

**Reviewer’s code:** 00505321

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Associate Professor

**Reviewer’s country:** United States

**Author’s country:** China

**Reviewer chosen by:** Le Zhang

**Reviewer accepted review:** 2019-12-05 00:33

**Reviewer performed review:** 2019-12-05 00:48

**Review time:** 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer’s expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

The authors conduct a review of 38 pts treated with Ruxilitinib for SR a or c GVHD. The doses were bid or qd and low. They report an encouraging very high response rate, except for Scleroderma changes. The report is irb approved, well organized, well written and contributes more information on this agent in this setting. It is not novel as the agent is approved in many countries for this use already. Further, there is concern on how dosing was chosen because the PK of the agent means it should be given BID and not QD unless you are about to discontinue use. Be that as it may, the results are encouraging.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- The same title
- Duplicate publication
- Plagiarism
- No

##### ***BPG Search:***

- The same title
- Duplicate publication
- Plagiarism
- No



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 52812

**Title:** Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: result from a retrospective study on 38 Chinese patients

**Reviewer’s code:** 03290441

**Position:** Peer Reviewer

**Academic degree:** MD, PhD

**Professional title:** Director

**Reviewer’s country:** Greece

**Author’s country:** China

**Reviewer chosen by:** Le Zhang

**Reviewer accepted review:** 2019-12-05 14:46

**Reviewer performed review:** 2019-12-08 19:00

**Review time:** 3 Days and 4 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer’s expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

1. Why were patients receiving other concomitant treatments for GVHD excluded? Ruxolitinib indication is not only as monotherapy. These patients could be included and sub-group analysis would indicate if concomitant treatment affected survival. 2. The authors report that ruxolitinib was administered as "add-on" treatment. This contra-indicates inclusion criteria. 3. Survival and cumulative incidence analysis should be also performed 4. Why was the follow-up so short? 5. Was ruxolitinib offered as second-line treatment after steroids in all patients? Which was the dose of steroids administered? 6. The discussion need to be shorter and to-the-point

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- The same title
- Duplicate publication
- Plagiarism
- No

##### ***BPG Search:***

- The same title
- Duplicate publication
- Plagiarism
- No